140 related articles for article (PubMed ID: 38071272)
1. Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease.
Pusic I; Lee C; Veeraputhiran M; Minor C; DiPersio JF
Bone Marrow Transplant; 2024 Feb; 59(2):282-284. PubMed ID: 38071272
[No Abstract] [Full Text] [Related]
2. ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease.
Hamad N; Bilmon I; Chee L; Henden A; Johnston A; Purtill D; Bajel A; Tey SK; Yeung D; Cole T; Lewis C; Butler J
Intern Med J; 2023 Dec; 53(12):2319-2329. PubMed ID: 38014511
[TBL] [Abstract][Full Text] [Related]
3. Severe relapses of cutaneous T-cell lymphoma after treatment of chronic graft-versus-host disease with ruxolitinib.
Cohen E; Bozonnat A; Battistella M; Calvani J; Vignon-Pennamen MD; Rivet J; Moins-Teisserenc H; Ta VA; Ram-Wolff C; Bouaziz JD; Mahevas T; Bagot M; Mourah S; Louveau B; Sicre de Fontbrune F; Peffault de Latour R; de Masson A; Battesti G
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e32-e34. PubMed ID: 37561935
[No Abstract] [Full Text] [Related]
4. Ruxolitinib Pharmacokinetics and Pharmacodynamics in Children with Acute and Chronic Graft-versus-Host Disease.
Cook E; Dong M; Chiang SCC; Luedeke D; Lake KE; Hoerth C; Deavy M; Setchell KDR; Zhao J; Punt N; Galletta T; Teusink-Cross A; Davies SM; Marsh RA; Mehta P; Khandelwal P
Transplant Cell Ther; 2024 May; 30(5):528.e1-528.e12. PubMed ID: 38401793
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.
Belina ME; Driscoll TA; Blanchard SK; Cardones AR
Pediatr Dermatol; 2022 May; 39(3):432-433. PubMed ID: 35234308
[TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis.
Baccelli F; Gottardi F; Muratore E; Leardini D; Grasso AG; Gori D; Belotti T; Prete A; Masetti R
Bone Marrow Transplant; 2024 Jun; 59(6):765-776. PubMed ID: 38402346
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib add-on therapy in steroid-refractory graft-vs-host disease following hematopoietic cell transplantation: A single institutional experience.
Wang YL; Chang TY; Wen YC; Yang SH; Hsiao YW; Chen SH; Jaing TH
Pediatr Neonatol; 2024 Jan; 65(1):85-86. PubMed ID: 37951828
[No Abstract] [Full Text] [Related]
8. A novel approach to visualize clinical benefit of therapies for chronic graft versus host disease (cGvHD): the probability of being in response (PBR) applied to the REACH3 study.
Hollaender N; Glimm E; Gauvin J; Stefanelli T; Zeiser R
Bone Marrow Transplant; 2024 Jan; 59(1):12-16. PubMed ID: 37898726
[TBL] [Abstract][Full Text] [Related]
9. Beyond ruxolitinib in steroid-refractory acute graft-versus-host disease.
Lee CJ; Pusic I; Savani BN
Br J Haematol; 2021 Nov; 195(3):306-307. PubMed ID: 34402041
[No Abstract] [Full Text] [Related]
10. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study.
Liu J; Fan Z; Xu N; Ye J; Chen Y; Shao R; Sun Y; Wu Q; Liu Q; Jin H
Ann Hematol; 2023 Oct; 102(10):2865-2877. PubMed ID: 37474631
[TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib for Chronic Graft-versus-Host Disease.
Shibusawa M
N Engl J Med; 2021 Oct; 385(17):1631. PubMed ID: 34670052
[No Abstract] [Full Text] [Related]
12. Ruxolitinib for Chronic Graft-versus-Host Disease.
Gratwohl A
N Engl J Med; 2021 Oct; 385(17):1631. PubMed ID: 34670051
[No Abstract] [Full Text] [Related]
13. Ruxolitinib for Chronic Graft-versus-Host Disease. Reply.
Zeiser R; Teshima T; Locatelli F
N Engl J Med; 2021 Oct; 385(17):1631-1632. PubMed ID: 34670053
[No Abstract] [Full Text] [Related]
14. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.
Xue E; Lorentino F; Pavesi F; Assanelli A; Peccatori J; Bernardi M; Corti C; Ciceri F; Lupo Stanghellini MT
Leuk Res; 2021 Oct; 109():106642. PubMed ID: 34157510
[TBL] [Abstract][Full Text] [Related]
15. New Indication for Ruxolitinib.
Aschenbrenner DS
Am J Nurs; 2022 Jan; 122(1):20. PubMed ID: 34941588
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib is an effective steroid sparing agent in children with steroid refractory/dependent bronchiolitis obliterans syndrome after allogenic hematopoietic cell transplantation.
Schoettler M; Duncan C; Lehmann L; Furutani E; Subramaniam M; Margossian S
Bone Marrow Transplant; 2019 Jul; 54(7):1158-1160. PubMed ID: 30683905
[No Abstract] [Full Text] [Related]
17. Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease.
Kaloyannidis P; Shaibani EA; Apostolidis I; Kanfar S; Anezi KA; Hashmi HA
Bone Marrow Transplant; 2019 May; 54(5):746-748. PubMed ID: 30337698
[No Abstract] [Full Text] [Related]
18. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease.
Abedin SM; Hamadani M
Expert Opin Investig Drugs; 2020 May; 29(5):423-427. PubMed ID: 32293938
[TBL] [Abstract][Full Text] [Related]
19. When is the best time and grade to start ruxolitinib in corticosteroid-refractory acute graft-versus-host-disease: A multi-center research.
Ren J; Lin K; Xu J; Lu Q; Luo Y; Lin C; Lu J; Weng Y; Zhang Y; Chen Z; Gale RP; Hu J; Yang T
Clin Transplant; 2024 Jan; 38(1):e15195. PubMed ID: 37987525
[TBL] [Abstract][Full Text] [Related]
20. Updates in chronic graft-versus-host disease management.
Malard F; Mohty M
Am J Hematol; 2023 Oct; 98(10):1637-1644. PubMed ID: 37483142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
